BioPharmSignal logoBioPharmSignal

Biotech News

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zura Bio (ZURA)Zura BioCompany update

HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 21, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory

Related news

ZURAZura Bio2026-08-31 20:30 EST

Zura Bio to Participate in the Cantor Global Healthcare Conference

CABACabaletta Bio2026-10-05 20:01 EST

Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

VERAVera Therapeutics2026-10-02 20:05 EST

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XFORX4 Pharmaceuticals2026-10-01 20:30 EST

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

AVTXAvalo Therapeutics2026-09-29 20:01 EST

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

ZURAZura Bio2026-08-11 11:30 EST

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

RNACCartesian Therapeutics2026-10-02 11:00 EST

Cartesian Therapeutics Announces New Employment Inducement Grants

INMBINmune Bio2026-10-06 13:00 EST

INmune Bio to Attend the 2026 Maxim Growth Summit

NRIXNurix Therapeutics2026-09-29 11:00 EST

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

SABSSAB Biotherapeutics2026-09-22 12:30 EST

SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes

View all latest news

Zura Bio

Autoimmune and Inflammatory Diseases Zura Bio develops biologics for serious autoimmune and inflammatory diseases, emphasizing combinations of validated immune pathways in single molecules. Tibulizumab Tibulizumab is a bispecific antibody designed to neutralize both IL-17 and BAFF. The dual mechanism targets inflammatory and B-cell...

Recent company news

ZURAZura Bio2026-08-31 20:30 EST

Zura Bio to Participate in the Cantor Global Healthcare Conference

ZURAZura Bio2026-08-21 23:57 EST

Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ZURAZura Bio2026-08-11 11:30 EST

Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates

ZURAZura Bio2026-06-29 11:30 EST

Zura Bio Exceeds Enrollment Target in Both Hidradenitis Suppurativa (HS) & Systemic Sclerosis (SSc) Phase 2 Studies and Expands Tibulizumab Program

ZURAZura Bio2026-05-14 11:30 EST

Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
3.96 USD
Market cap
389.01M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States